Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01174368 · ClinicalTrials.gov registry record · Phase 2
Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T
A Phase 2 study, sponsored by The Rogosin Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT01174368 is a Phase 2 study that has completed, run by The Rogosin Institute. The registered enrollment target is 1 participants.
The verdict
NCT01174368, a Phase 2 study, has completed, sponsored by The Rogosin Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a clinical research study of an investigational (FDA IND-BB 10091) treatment of subjects with castration-resistant prostate cancer resistant to Taxanes (docetaxel, cabazitaxel) and evidence of disease progression on androgen-axis inhibition and/or immunotherapy in the form of sipuleucel-T. The treatment is being evaluated for its effect on tumor growth. It consists of the placement (implantation) of small beads that contain mouse renal adenocarcinoma cells (RENCA macrobeads). The cells in the macrobeads produce substances that have been shown to slow or stop the growth of tumors in experimental animals and veterinary patients. It has been tested in 31 human subjects with different types of cancers in a Phase I safety trial. Phase II studies in patients with colorectal, pancreatic or prostate cancers are in progress.
Interventions
- BIOLOGICAL Cancer Macrobead placement in abdominal cavity
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-06 |
| Est. Completion | 2017-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01174368
The ClinicalTrials.gov registry entry for NCT01174368 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Rogosin Institute, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cancer Macrobead placement in abdominal cavity is the first listed.
NCT01174368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01174368 about?
NCT01174368 is a clinical study titled "Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T". This is a clinical research study of an investigational (FDA IND-BB 10091) treatment of subjects with castration-resistant prostate cancer resistant to Taxanes (docetaxel, cabazitaxel) and evidence of disease progression on androgen-axis inhibition and/or immunotherapy in the form of sipuleucel-T. ...
What is the current status of trial NCT01174368?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2010-06. Estimated completion is 2017-04.
What interventions are being tested in trial NCT01174368?
The interventions under investigation include: Cancer Macrobead placement in abdominal cavity (BIOLOGICAL).
Who is sponsoring clinical trial NCT01174368?
This trial is sponsored by The Rogosin Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.